Compare RTX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | NVO |
|---|---|---|
| Founded | 1934 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.3B | 212.7B |
| IPO Year | N/A | N/A |
| Metric | RTX | NVO |
|---|---|---|
| Price | $181.80 | $50.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $177.57 | $54.25 |
| AVG Volume (30 Days) | 4.6M | ★ 18.5M |
| Earning Date | 01-27-2026 | 02-04-2026 |
| Dividend Yield | 1.52% | ★ 2.45% |
| EPS Growth | ★ 38.64 | 10.06 |
| EPS | ★ 4.87 | 3.67 |
| Revenue | ★ $85,988,000,000.00 | $49,580,393,058.00 |
| Revenue This Year | $8.82 | $7.77 |
| Revenue Next Year | $6.17 | $1.86 |
| P/E Ratio | $36.69 | ★ $13.69 |
| Revenue Growth | 8.79 | ★ 16.64 |
| 52 Week Low | $112.27 | $43.08 |
| 52 Week High | $181.31 | $111.17 |
| Indicator | RTX | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 55.77 |
| Support Level | $170.35 | $46.08 |
| Resistance Level | $172.09 | $50.75 |
| Average True Range (ATR) | 3.45 | 1.07 |
| MACD | 0.93 | 0.54 |
| Stochastic Oscillator | 99.48 | 92.93 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.